U.S. market Closed. Opens in 17 hours 16 minutes

YS | YS Biopharma Co., Ltd. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-03-312022-03-312021-03-31
Revenue687.20M502.95M257.02M
Cost of Revenue153.36M117.07M59.66M
Gross Profit533.84M385.88M197.36M
Operating Expenses647.15M481.82M319.68M
Selling, General & Admin333.32M272.77M208.33M
Research & Development318.70M211.22M94.39M
Other Operating Expenses-199.45K-2.41M-22.36M
Operating Income-139.38M-118.96M-125.85M
Other Expenses / Income-178.09K-2.41M-22.36M
Before Tax Income-144.35M-101.07M-174.37M
Income Tax Expenses1.13M4.94M17.45M
Net Income-145.48M-106.00M-191.83M
Interest Expenses30.86M2.72M29.69M
Basic Shares Outstanding93.06M92.17M92.17M
Diluted Shares Outstanding93.06M92.17M92.17M
EBITDA-76.82M-67.20M-116.78M
EBITDA Margin-11.18%-13.36%-45.44%
EBIT-113.49M-98.35M-144.68M
EBIT Margin-16.51%-19.55%-56.29%
Financial Year End2023-03-312022-03-312021-03-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙